4G/5G promoter polymorphism of plasminogen activator inhibitor-1, lipid profiles, and ischemic stroke

Journal of Laboratory and Clinical Medicine

Volumn 142, Issue 2, 2003, Pages 100-105

  Chen, Chih Hung ^b   Eng, Hock Liew ^b   Chang, Chih Jen ^b   Tsai, Tzu Tung ^b   Lai, Ming Liang ^b   Chen, Hsiao Yen ^b   Liu, Chien Ju ^b   Lin, Tsun Mei ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL;

ADULT; AGED; ALLELE; ARTICLE; CEREBROVASCULAR ACCIDENT; CHINESE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN CELL; HYPERTENSION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PROMOTER REGION; REGRESSION ANALYSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; SMOKING; TAIWAN; THROMBOSIS;

EID: 0141630329     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2143(03)00063-5     Document Type: Article

References (27)

1. Adams HP Jr, Bendixen BH, Kappelle LJ, Billet J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment. Stroke 1993;24:35-41.
2. Sacco RL, Ellenberg JH, Mohr JP, Tatemichi TK, Hier DB, Price TR, et al. Infarcts of undetermined cause: the NINCDS Stroke Data Bank. Ann Neurol 1989;25:382-90.
3. Simmonds RE, Hermida J, Rezende SM, Lane DA. Haemostatic genetic risk factors in arterial thrombosis. Thromb Haemost 2001;86:374-85.
4. Pannekoek H, Veerman H, Lambers H, Diergaarde P, Verweij CL, van Zonneveld AJ, et al. Endothelial plasminogen activator inhibitor (PAI): a new member of the Serpin gene family. EMBO J 1986;5:2539-44.
5. Juhan-Vague I, Pyke SD, Alessi MC, Jespersen J, Haverkate F, Thompson SG. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group: European Concerted Action on Thrombosis and Disabilities. Circulation 1996;94:2057-63.
6. Lindgren A, Lindoff C, Norrving B, Astedt B, Johansson BB. Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients. Stroke 1996;27:1066-71.
7. Juhan-Vague I, Roul C, Alessi MC, Ardissone JP, Heim M, Vague P. Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients; relationship with plasma insulin. Thromb Haemost 1989;61:370-3.
8. Dawson S, Hamsten A, Wiman B, Henney A, Humphries S. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb 1991;11:183-90.
9. Dawson SJ, Wiman B, Hamsten A, Greek F, Humphries S, Henney A. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1991;268:10739-45.
10. Eriksson P, Kallin B, van't Hooft FM, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A 1995;92:1851-5.
11. Ossei-Gerning N, Mansfield MW, Stickland MH, Wilson IJ, Grant PJ. Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography. Arterioscler Thromb Vasc Biol 1997;17:33-7.
12. Iacoviello L, Burzotta F, Di Castelnuovo A, Zito F, Marchioli R, Donati MB. The 4G/5G polymorphism of PAI-1 promoter gene and the risk of myocardial infarction: a meta-analysis. Thromb Haemost 1998;80:1029-30.
13. Ye S, Green FR, Scarabin PY, Nicaud V, Bara L, Dawson SJ, et al. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTLM study. Etude CasTemoins de I'nfarctus du Mycocarde. Thromb Haemost 1995;74:837-41.
14. Burzotta F, Di Castelnuovo A, Amore C, D'Orazio A, Donati MB, Iacoviello L. 4G/5G polymorphism in the promoter region of the PAI-1 gene is not a risk factor for familial myocardial infarction in subjects over 45 years. Thromb Haemost 1997;78:1294-5.
15. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Miletich JP. Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men. Circulation 1997;95:59-62.
16. Catto AJ, Carter AM, Stickland M, Bamford JM, Davies JA, Grant PJ. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphism and levels in subjects with cerebrovascular disease. Thrmob Haemost 1997;77:730-4.
17. Bang CO, Park HK, Ahn MY, Shin HK, Hwang KY, Hong SY. 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene and insertion/deletion polymorphism of the tissue-type plasminogen activator gene in atherothrombotic stroke. Cerebrovasc Dis 2001;11:294-9.
18. Endler G, Lalouschek W, Exner M, Mitterbauer G, Haring D, Mannhalter C. The 4G/4G genotype at nucleotide position -675 in the promotor region of the plasminogen activator inhibitor 1 (PAI-1) gene is less frequent in young patients with minor stroke than in controls. Br J Haematol 2000;110:469-71.
19. Roest M, van der Schouw YT, Banga JD, Tempelman MJ, de Groot PG, Sixma JJ, et al. Plasminogen activator inhibitor 4G polymorphism is associated with decreased risk of cerebrovascular mortality in older women. Circulation 2000;101:67-70.
20. Rossaak JI, van Rij AM, Jones GT, Harris EL. Association of the 4G/SG polymorphism in the promoter region of plasminogen activator inhibitor-1 with abdominal aortic aneurysms. J Vasc Surg 2000;31:1026-32.
21. Song J, Yoon YM, Jung HJ, Hong SH, Park H, Kim JQ. Plasminogen activator inhibitor-1 4G/5G promoter polymorphism and coagulation factor VII Arg353→Gln polymorphism in Korean patients with coronary artery disease. J Korean Med Sci 2000;15:146-52.
22. Wang AY, Poon P, Lai FM, Yu L, Choi PC, Lui SF, et al. Plasminogen activator inhibitor-1 gene polymorphism 4G/4G genotype and lupus nephritis in Chinese patients. Kidney Int 2001;59:1520-8.
23. Matsuhara Y, Murata M, Isshiki I, Watanahe R, Zama T, Watanahe G, et al. Genotype frequency of plasminogen activator inhibitor (PAI-1) 4G/SG polymorphism in healthy Japaneses males and its trlation to PAI-1 levels. Int J Hematol 1999;69:43-7.
24. Anderson JL, Muhlestein JB, Hahashi J, Carlquist JF, Bair TL, Elmer SP, et al. Lack of association of a common polymorphism of the plasminogen activator inhibitor-1 gene with coronary artery disease and myocardial infaction. J Am Coll Cardiol 1999;34:1778-83.
25. Doggen CJ, Bertina RM, Cats VM, Reitsma PH, Rosendaal FR. The 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is not associated with myocardial infarction. Thromb Haemost 1999;82:115-20.
26. Eriksson P, Nilsson L, Hamsten A. Very-low-density lipoprotein response element in the promoter region of human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemias. Arterioscler Thromh Vasc Biol 1997;18:20-6.
27. Woo J, Lam CW, Kay R, Wong HY, Teoh R, Nicholls MG. Acute and long-term changes in serum lipids after acute stroke. Stroke 1990;21:1407-11.